Hospital Universitario de Canarias -ko ikertzaileekin lankidetzan egindako argitalpenak (62)

2024

  1. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  2. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  2. Granulocytic Sarcoma Mimicking Cholesteatoma: Beware the Temporal Bone in Haematological Patients

    ORL, Vol. 85, Núm. 5, pp. 299-304

  3. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  4. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456

2022

  1. Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (Annals of Hematology, (2022), 101, 10, (2231-2239), 10.1007/s00277-022-04963-z)

    Annals of Hematology

  2. Hb Nivaria: A New Hemoglobin Variant with a Shortened α-Globin Chain [α139(HC1)Lys→Stop; HBA1: c.418A>T]

    Hemoglobin, Vol. 46, Núm. 6, pp. 344-346

  3. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

    Cancers, Vol. 14, Núm. 9

  4. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  5. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  6. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

  7. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: a single center's experience

    Revista Clinica Espanola, Vol. 222, Núm. 3, pp. 169-173

2021

  1. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

    American Journal of Hematology, Vol. 96, Núm. 10, pp. 1186-1194

  2. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 371-379

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

2019

  1. Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia

    Revista Clinica Espanola, Vol. 219, Núm. 8, pp. 440-444

  2. Nasal embryonal rhabdomyosarcoma with bone marrow metastasis simulating acute leukemia: A case report and review of the literature

    Revista Espanola de Patologia, Vol. 52, Núm. 2, pp. 87-91

2018

  1. Bone marrow trephine biopsy in Hodgkin's lymphoma. Comparison with PET-CT scan in 65 patients

    Medicina Clinica, Vol. 150, Núm. 3, pp. 104-106

  2. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology